ClinicalTrials.gg
CompletedNCT00389441Updated Nov 25, 2013Results posted

Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

A Phase 2 interventional study of AG-013736 in Thyroid Neoplasms, sponsored by Pfizer. Completed at 26 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-25.

Sponsored by Pfizer · Phase 2 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 283 studies in Thyroid Neoplasms with a site in United States — 54 open to participants now, 90 under way, 3 of them phase 3. Thyroid Neoplasms · United States.

Enrollment
85th of 231
52 · median 35
Started
2006
with 11 others
Phase 2
99 of 283
12 open now
Registered
41st of 283
by date
Lead sponsor
5 of 283
Pfizer

Among the 283 studies in Thyroid Neoplasms with a site in United States, this one is the 85th largest by enrollment of the 231 interventional ones that give a count, is one of 12 that started in 2006, is one of 99 in phase 2, and was the 41st registered.

Thyroid Neoplasms

785 studies on the registry are indexed under Thyroid Neoplasms; 204 are open to participants now.

Browse Thyroid Neoplasms studies →

Open to participants now

54 of the 283 studies in Thyroid Neoplasms with a site in United States are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 152 Thyroid Neoplasms studies recruiting now, 96 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 37 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Thyroid Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The primary purpose is to determine how effective AG-013736 is in shrinking thyroid cancer that is resistant to radioactive iodine

Read the detailed description

Additional study details: assess safety and efficacy

03

Conditions studied

  • Thyroid Neoplasms

Keywords

  • VEGFR inhibitor
  • tyrosine kinase inhibitor
  • anti-angiogenic
  • carcinoma
  • papillary
  • follicular
  • medullary
  • anaplastic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Radioiodine- or unresectable locally-advanced thyroid cancer
  • At least 1 measurable target lesion, as defined by

Exclusion criteria

Exclusion Criteria:

  • Thyroid lymphoma
  • Previous treatment with anti-angiogenesis agents
  • No myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or , deep vein thrombosis or pulmonary embolism within 12 months prior.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    A

    Drug: AG-013736

Interventions

  • AG-013736, tablets 5 mg BID , treatment will continue until tumor progression or toxicity

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Objective Response (OR)

    Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST). CR: disappearance of all target/non-target lesions and no appearance of new lesions. PR: at least (\>=)30 percent(%) decrease in sum of the longest dimensions (LDs) of the target lesions (taking as a reference the baseline sum), without progression of non-target lesions and no appearance of new lesions. Confirmed responses: those persist on repeat imaging study \>=4 weeks after initial documentation of response.

    Time frame: Baseline until disease progression or initiation of antitumor therapy or death due to any cause, assessed every 8 weeks up to 28 days after last dose (follow-up)

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS: Time in weeks from the start of study treatment to first documentation of objective disease progression or to death due to any cause, whichever occurred first. PFS was calculated as (first event date minus the date of first dose of study treatment plus 1) divided by 7. Progression is defined using RECIST, as \>=20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD since start of study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

    Time frame: Baseline until disease progression or initiation of antitumor therapy or death due to any cause, assessed every 8 weeks up to 28 days after last dose (follow-up)

  2. Duration of Response (DR)

    Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

    Time frame: Baseline until disease progression or initiation of antitumor therapy or death due to any cause, assessed every 8 weeks up to 28 days after last dose (follow-up)

  3. Overall Survival (OS)

    Time in weeks from the start of study treatment to date of death due to any cause. OS was calculated as (the death date minus the date of first dose of study medication plus 1) divided by 7. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).

    Time frame: Baseline to death due to any cause or at least 2 year after the first dose for the last participant

  4. Change From Baseline in MD Anderson Symptom Assessment Inventory (MDASI) Symptom Severity Score

    Symptom severity score is comprised of average of 13 MDASI core items (pain, fatigue, nausea, disturbed sleep, distressed, shortness of breath, remembering things, lack of appetite, drowsy, dry mouth, sadness, vomiting, numbness or tingling). Participants were asked to rate severity of each symptom at their worst in last 24 hours; each item rated from 0 to 10, with 0 = symptom not present and 10 = as bad as you can imagine. Total average score range: 0 to 10. Lower scores indicated better outcome.

    Time frame: Baseline, Cycle 1 Day 15 (C1D15), C2D1, C2D15, thereafter D1 of each cycle up to 28 days after last dose (follow-up)

  5. Change From Baseline in MD Anderson Symptom Assessment Inventory (MDASI) Symptom Interference Score

    Symptom interference score is comprised of average of 6 function items from MDASI core (general activity, mood, work, relations with others, walking, and enjoyment of life). Participants were asked to rate how much symptoms have interfered in last 24 hours; each item rated from 0 to 10, with 0 = did not interfere and 10 = interfered completely. Total average score range: 0 to 10. Lower scores indicated better outcome.

    Time frame: Baseline, Cycle 1 Day 15 (C1D15), C2D1, C2D15, thereafter D1 of each cycle up to 28 days after last dose (follow-up)

07

Results

Posted Nov 25, 2013

Participant flow

Participant flow — Overall Study
MilestoneAxitinib
Started52
Completed0
Not completed52
Withdrew: Adverse event7
Withdrew: Death4
Withdrew: Lost to follow-up2
Withdrew: Withdrawal by subject4
Withdrew: Physician decision1
Withdrew: Protocol violation1
Withdrew: Global deterioration of health status4
Withdrew: Objective progression or relapse26
Withdrew: Ongoing in study a4061008 (nct00828919)2
Withdrew: Clinical progression1

Outcome measures

PrimaryPercentage of Participants With Objective Response (OR)

Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST). CR: disappearance of all target/non-target lesions and no appearance of new lesions. PR: at least (\>=)30 percent(%) decrease in sum of the longest dimensions (LDs) of the target lesions (taking as a reference the baseline sum), without progression of non-target lesions and no appearance of new lesions. Confirmed responses: those persist on repeat imaging study \>=4 weeks after initial documentation of response.

Time frame:
Baseline until disease progression or initiation of antitumor therapy or death due to any cause, assessed every 8 weeks up to 28 days after last dose (follow-up)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response (OR)
percentage of participantsAxitinib
Percentage of Participants With Objective Response (OR)34.6 (22.0 to 49.1)
SecondaryProgression Free Survival (PFS)

PFS: Time in weeks from the start of study treatment to first documentation of objective disease progression or to death due to any cause, whichever occurred first. PFS was calculated as (first event date minus the date of first dose of study treatment plus 1) divided by 7. Progression is defined using RECIST, as \>=20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD since start of study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

Time frame:
Baseline until disease progression or initiation of antitumor therapy or death due to any cause, assessed every 8 weeks up to 28 days after last dose (follow-up)
Reported as:
Median · weeks
Progression Free Survival (PFS)
weeksAxitinib
Progression Free Survival (PFS)70.14 (64.14 to 93.71)
SecondaryDuration of Response (DR)

Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

Time frame:
Baseline until disease progression or initiation of antitumor therapy or death due to any cause, assessed every 8 weeks up to 28 days after last dose (follow-up)
Reported as:
Median · weeks
Duration of Response (DR)
weeksAxitinib
Duration of Response (DR)74.71 (59.14 to 112.29)
SecondaryOverall Survival (OS)

Time in weeks from the start of study treatment to date of death due to any cause. OS was calculated as (the death date minus the date of first dose of study medication plus 1) divided by 7. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).

Time frame:
Baseline to death due to any cause or at least 2 year after the first dose for the last participant
Reported as:
Median · weeks
Overall Survival (OS)
weeksAxitinib
Overall Survival (OS)118.43 (63.57 to 174.57)
SecondaryChange From Baseline in MD Anderson Symptom Assessment Inventory (MDASI) Symptom Severity Score

Symptom severity score is comprised of average of 13 MDASI core items (pain, fatigue, nausea, disturbed sleep, distressed, shortness of breath, remembering things, lack of appetite, drowsy, dry mouth, sadness, vomiting, numbness or tingling). Participants were asked to rate severity of each symptom at their worst in last 24 hours; each item rated from 0 to 10, with 0 = symptom not present and 10 = as bad as you can imagine. Total average score range: 0 to 10. Lower scores indicated better outcome.

Time frame:
Baseline, Cycle 1 Day 15 (C1D15), C2D1, C2D15, thereafter D1 of each cycle up to 28 days after last dose (follow-up)
Reported as:
Mean · units on a scale
Change From Baseline in MD Anderson Symptom Assessment Inventory (MDASI) Symptom Severity Score
units on a scaleAxitinib
Baseline (n= 49)1.66 ± 1.301
Change at C1D15 (n= 40)0.18 ± 1.158
Change at C2D1 (n= 42)0.43 ± 1.274
Change at C2D15 (n= 37)0.52 ± 1.407
Change at C3D1 (n= 43)0.53 ± 1.602
Change at C4D1 (n= 39)0.58 ± 1.199
Change at C5D1 (n= 36)0.69 ± 1.550
Change at C6D1 (n= 36)0.53 ± 1.484
Change at C7D1 (n= 29)0.40 ± 1.344
Change at C8D1 (n= 28)0.44 ± 1.395
Change at C9D1 (n= 27)0.56 ± 1.516
Change at C10D1 (n= 25)0.59 ± 1.494
Change at C11D1 (n= 25)0.63 ± 1.669
Change at C12D1 (n= 24)0.59 ± 1.584
Change at C13D1 (n= 24)0.60 ± 1.281
Change at C14D1 (n= 24)0.59 ± 1.476
Change at C15D1 (n= 24)0.76 ± 1.654
Change at C16D1 (n= 23)0.81 ± 1.911
Change at C17D1 (n= 20)0.73 ± 1.816
Change at C18D1 (n= 20)0.60 ± 1.729
Change at C19D1 (n= 18)0.40 ± 1.201
Change at C20D1 (n= 16)0.50 ± 0.864
Change at C21D1 (n= 16)0.84 ± 1.094
Change at C22D1 (n= 15)0.61 ± 0.970
Change at C23D1 (n= 14)0.87 ± 1.086
Change at C24D1 (n= 11)1.05 ± 0.990
Change at C25D1 (n= 11)0.87 ± 1.016
Change at C26D1 (n= 9)1.15 ± 0.960
Change at C27D1 (n= 9)1.19 ± 1.244
Change at C28D1 (n= 10)0.95 ± 1.291
Change at C29D1 (n= 10)0.98 ± 1.080
Change at C30D1 (n= 10)1.03 ± 0.970
Change at C31D1 (n= 9)1.14 ± 1.100
Change at C32D1 (n= 9)1.44 ± 1.058
Change at C33D1 (n= 9)1.32 ± 1.233
Change at C34D1 (n= 8)1.54 ± 1.366
Change at C35D1 (n= 6)1.29 ± 1.233
Change at C36D1 (n= 6)1.27 ± 1.610
Change at C37D1 (n= 5)1.48 ± 1.347
Change at C38D1 (n= 5)1.27 ± 1.117
Change at C39D1 (n= 5)1.49 ± 1.288
Change at C40D1 (n= 5)1.47 ± 1.176
Change at C41D1 (n= 5)1.48 ± 1.267
Change at C42D1 (n= 5)1.59 ± 1.312
Change at C43D1 (n= 5)1.59 ± 1.259
Change at C44D1 (n= 5)1.42 ± 1.258
Change at C45D1 (n= 4)1.49 ± 1.349
Change at C46D1 (n= 4)1.73 ± 1.425
Change at C47D1 (n= 4)1.70 ± 1.543
Change at C48D1 (n= 3)1.90 ± 1.377
Change at C49D1 (n= 3)2.26 ± 1.554
Change at C50D1 (n= 3)2.38 ± 1.425
Change at C51D1 (n= 3)2.46 ± 1.533
Change at C52D1 (n= 1)3.38 ± NA
Change at C53D1 (n= 1)3.54 ± NA
Change at C54D1 (n= 1)3.00 ± NA
Change at C55D1 (n= 1)3.38 ± NA
Change at C56D1 (n= 1)3.15 ± NA
Change at C57D1 (n= 1)3.62 ± NA
Change at C58D1 (n= 1)3.23 ± NA
Change at C59D1 (n= 1)3.08 ± NA
Change at C60D1 (n= 1)3.85 ± NA
Change at C61D1 (n= 1)3.31 ± NA
Change at C62D1 (n= 1)3.46 ± NA
Change at follow-up (n= 12)0.37 ± 0.939
SecondaryChange From Baseline in MD Anderson Symptom Assessment Inventory (MDASI) Symptom Interference Score

Symptom interference score is comprised of average of 6 function items from MDASI core (general activity, mood, work, relations with others, walking, and enjoyment of life). Participants were asked to rate how much symptoms have interfered in last 24 hours; each item rated from 0 to 10, with 0 = did not interfere and 10 = interfered completely. Total average score range: 0 to 10. Lower scores indicated better outcome.

Time frame:
Baseline, Cycle 1 Day 15 (C1D15), C2D1, C2D15, thereafter D1 of each cycle up to 28 days after last dose (follow-up)
Reported as:
Mean · units on a scale
Change From Baseline in MD Anderson Symptom Assessment Inventory (MDASI) Symptom Interference Score
units on a scaleAxitinib
Baseline (n= 48)2.24 ± 2.193
Change at C1D15 (n= 40)-0.05 ± 2.161
Change at C2D1 (n= 41)0.28 ± 2.763
Change at C2D15 (n= 36)0.67 ± 2.403
Change at C3D1 (n= 42)0.46 ± 2.669
Change at C4D1 (n= 37)0.47 ± 2.311
Change at C5D1 (n= 36)0.50 ± 2.377
Change at C6D1 (n= 36)0.65 ± 2.605
Change at C7D1 (n= 29)0.19 ± 2.386
Change at C8D1 (n= 28)0.22 ± 2.242
Change at C9D1 (n= 27)0.46 ± 2.450
Change at C10D1 (n= 25)0.35 ± 2.386
Change at C11D1 (n= 25)0.51 ± 2.784
Change at C12D1 (n= 23)0.32 ± 2.593
Change at C13D1 (n= 24)0.42 ± 2.346
Change at C14D1 (n= 24)0.42 ± 2.624
Change at C15D1 (n= 24)0.69 ± 2.902
Change at C16D1 (n= 23)0.73 ± 3.179
Change at C17D1 (n= 20)0.26 ± 2.920
Change at C18D1 (n= 20)0.35 ± 2.638
Change at C19D1 (n= 18)-0.18 ± 2.497
Change at C20D1 (n= 15)0.30 ± 2.124
Change at C21D1 (n= 15)0.50 ± 1.954
Change at C22D1 (n= 14)0.32 ± 1.979
Change at C23D1 (n= 14)0.95 ± 1.615
Change at C24D1 (n= 11)0.77 ± 1.844
Change at C25D1 (n= 11)0.65 ± 1.699
Change at C26D1 (n= 9)1.04 ± 1.681
Change at C27D1 (n= 9)0.81 ± 2.463
Change at C28D1 (n= 28)0.67 ± 1.956
Change at C29D1 (n= 29)0.88 ± 1.926
Change at C30D1 (n= 30)1.03 ± 1.846
Change at C31D1 (n= 9)1.19 ± 1.910
Change at C32D1 (n= 9)1.52 ± 1.870
Change at C33D1 (n= 9)1.07 ± 1.972
Change at C34D1 (n= 8)1.81 ± 1.846
Change at C35D1 (n= 6)1.17 ± 1.517
Change at C36D1 (n= 6)0.97 ± 1.572
Change at C37D1 (n= 5)1.40 ± 1.782
Change at C38D1 (n= 5)1.23 ± 1.521
Change at C39D1 (n= 5)1.50 ± 1.453
Change at C40D1 (n= 5)1.83 ± 1.889
Change at C41D1 (n= 5)1.53 ± 1.746
Change at C42D1 (n= 5)1.67 ± 1.637
Change at C43D1 (n= 5)1.31 ± 1.267
Change at C44D1 (n= 5)1.34 ± 1.345
Change at C45D1 (n= 4)1.50 ± 1.694
Change at C46D1 (n= 4)2.17 ± 2.113
Change at C47D1 (n= 4)1.63 ± 1.950
Change at C48D1 (n= 3)2.00 ± 1.041
Change at C49D1 (n= 3)2.56 ± 1.798
Change at C50D1 (n= 3)0.22 ± 1.206
Change at C51D1 (n= 3)2.44 ± 1.251
Change at C52D1 (n= 1)3.33 ± NA
Change at C53D1 (n= 1)3.33 ± NA
Change at C54D1 (n= 1)3.33 ± NA
Change at C55D1 (n= 1)3.50 ± NA
Change at C56D1 (n= 1)3.50 ± NA
Change at C57D1 (n= 1)4.50 ± NA
Change at C58D1 (n= 1)3.67 ± NA
Change at C59D1 (n= 1)3.33 ± NA
Change at C60D1 (n= 1)4.83 ± NA
Change at C61D1 (n= 1)3.33 ± NA
Change at C62D1 (n= 1)4.00 ± NA
Change at follow-up (n= 12)0.32 ± 2.396

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axitinib—22/52 (42.3%)52/52 (100%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventAxitinib
FatigueGeneral disorders3/52
DyspnoeaRespiratory, thoracic and mediastinal disorders3/52
Disease progressionGeneral disorders2/52
Weight decreasedInvestigations2/52
Cardiac failure congestiveCardiac disorders1/52
Hypertensive heart diseaseCardiac disorders1/52
Myocardial infarctionCardiac disorders1/52
Myocardial ischaemiaCardiac disorders1/52
HaematemesisGastrointestinal disorders1/52
Oral painGastrointestinal disorders1/52
Most frequent other events
Showing 10 of 228
Most frequent other events
EventAxitinib
DiarrhoeaGastrointestinal disorders31/52
HypertensionVascular disorders28/52
FatigueGeneral disorders23/52
Decreased appetiteMetabolism and nutrition disorders19/52
Weight decreasedInvestigations18/52
Pain in extremityMusculoskeletal and connective tissue disorders16/52
NauseaGastrointestinal disorders14/52
DyspnoeaRespiratory, thoracic and mediastinal disorders12/52
CoughRespiratory, thoracic and mediastinal disorders11/52
Mucosal inflammationGeneral disorders10/52

Baseline characteristics

Age Continuous
Age Continuous(years)Axitinib
Mean57.6 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Axitinib
Female24
Male28
08

Study locations

26 sites
  • Pfizer Investigational Site
    Orange, California 92868, United States
  • Pfizer Investigational Site
    Aurora, Colorado 80010, United States
  • Pfizer Investigational Site
    Tampa, Florida 33612, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60637-1470, United States
  • Pfizer Investigational Site
    Wichita, Kansas 67226, United States
  • Pfizer Investigational Site
    Witchita, Kansas 67220, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02114, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02115, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02215, United States
  • Pfizer Investigational Site
    Buffalo, New York 14263, United States
  • Pfizer Investigational Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Pfizer Investigational Site
    London, Ontario N6A 4L6, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H2L 4M1, Canada
  • Pfizer Investigational Site
    Nanjing, Jiangsu 210002, China
  • Pfizer Investigational Site
    Beijing, 100021, China
  • Pfizer Investigational Site
    Shanghai, 20001/200127, China
  • Pfizer Investigational Site
    Shanghai, 200233, China
  • Pfizer Investigational Site
    Praha 5, 150 06, Czech Republic
  • Pfizer Investigational Site
    Vellore, Tamil Nadu 632 004, India
  • Pfizer Investigational Site
    Milano, 20133, Italy
  • Pfizer Investigational Site
    Pisa, 56124, Italy
  • Pfizer Investigational Site
    Gliwice, 44-101, Poland
  • Pfizer Investigational Site
    Warszawa, 02-781, Poland
  • Pfizer Investigational Site
    Pamplona, Navarra 31008, Spain
  • Pfizer Investigational Site
    Madrid, 28033, Spain
  • Pfizer Investigational Site
    Glasgow, G12 0YN, United Kingdom
09

References and documents

Publications

  • Locati LD, Licitra L, Agate L, Ou SH, Boucher A, Jarzab B, Qin S, Kane MA, Wirth LJ, Chen C, Kim S, Ingrosso A, Pithavala YK, Bycott P, Cohen EE. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer. 2014 Sep 1;120(17):2694-703. doi: 10.1002/cncr.28766. Epub 2014 May 20. PubMed 24844950 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2006
First posted
Oct 18, 2006
Start
Dec 2006
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Results first posted
Nov 25, 2013
Last update
Nov 25, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00389441
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 18, 2006
Start date
Dec 2006
Primary completion
Sep 2012
Completion
Sep 2012
Results posted
Nov 25, 2013
Last update
Nov 25, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion